Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

KAILUA KONA, Hawaii--(BUSINESS WIRE)-- Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025.

Commenting on the first quarter of fiscal year 2026 results, Cyanotech’s President and Chief Executive Officer, Matthew K. Custer, said:

“While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency.”

“We remain focused on executing our long-term strategy. This includes driving brand value through differentiated storytelling, deepening relationships in key e-commerce and bulk ingredient markets, and focusing on sustainable cash flows.”

“As we navigate the continued macroeconomic challenges, I am proud of the resilience our team has shown and am confident in the progress that we are making.”

First Quarter Fiscal 2026

Cyanotech reported net sales of $5,820,000 for the first quarter of fiscal 2026 compared to $5,898,000 for the first quarter of fiscal 2025, a decrease of 1.3%. Gross profit was $1,773,000, with gross profit margin of 30.5%, compared to gross profit of $1,476,000, with gross profit margin of 25.0%. Operating loss for the first quarter of fiscal 2026 was $753,000 compared to operating loss of $1,041,000 in the same period of the prior year. Net loss for the current fiscal quarter was $926,000, or $0.13 per diluted share, compared to net loss of $1,202,000, or $0.17 per diluted share, for the same period of the prior year.

Trailing Twelve Months

For the trailing twelve months ended June 30, 2025, compared to the trailing twelve months ended June 30, 2024, net sales were $24,137,000 compared to $23,824,000, respectively. Gross profit was $7,172,000, with gross profit margin of 29.7%, compared to $5,889,000 and 24.7%. Net loss was $2,927,000, or $0.41 per diluted share, compared to net loss of $5,100,000, or $0.76 per diluted share.

Please review the Company’s Form 10-Q for the period ended June 30, 2025 for more detailed information.

— Cyanotech will host a virtual broadcast at 8:00 PM ET on Thursday, August 7, 2025 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@cyanotech.com before 12 p.m. (noon) ET on Thursday, August 7, 2025. The Company will respond only to relevant questions relating to the Company’s first quarter fiscal 2026 financial performance and will not be accepting any questions or comments during the broadcast.

To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.

About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 40 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company’s mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech’s BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise†. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity†. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (“GRAS”) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit www.cyanotech.com for more information.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-Q for the first quarter fiscal 2026 ended June 30, 2025, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such, the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

CYANOTECH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited)
		June 30, 2025				March 31, 2025
ASSETS
Current assets:
Cash		$	383			$	257
Accounts receivable, net of allowance for credit losses of $16 as of June 30, 2025 and March 31, 2025			1,560				1,953
Inventories			8,110				7,788
Prepaid expenses and other current assets			470				547
Total current assets			10,523				10,545
Equipment and leasehold improvements, net			8,590				8,927
Operating lease right-of-use assets, net			3,769				3,902
Other assets			113				116
Total assets		$	22,995			$	23,490
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	2,234			$	2,217
Accrued expenses			740				715
Customer deposits			106				110
Operating lease obligations, current portion			566				555
Short term debt - bank			565				760
Line of credit – related party			3,750				3,000
Current maturities of long-term debt			2,817				2,886
Total current liabilities			10,778				10,243
Long-term debt – related party			1,000				1,000
Long-term operating lease obligations			3,217				3,363
Total liabilities			14,995				14,606
Commitments and contingencies
Stockholders’ equity:
Preferred stock of $0.01 par value, 10,000,000 shares authorized; no shares issued and outstanding			—				—
Common stock of $0.02 par value, 50,000,000 shares authorized; 7,232,217 shares at June 30, 2025 and 7,199,908 shares at March 31, 2025 issued and outstanding			145				144
Additional paid-in capital			34,885				34,844
Accumulated deficit			(27,030	)			(26,104	)
Total stockholders’ equity			8,000				8,884
Total liabilities and stockholders’ equity		$	22,995			$	23,490

CYANOTECH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands) (Unaudited)
		Three Months Ended June 30,
		2025				2024
Net sales		$	5,820			$	5,898
Cost of sales			4,047				4,422
Gross profit			1,773				1,476
Operating expenses:
General and administrative			1,300				1,268
Sales and marketing			1,152				1,165
Research and development			74				84
Total operating expenses			2,526				2,517
Loss from operations			(753	)			(1,041	)
Interest expense, net			(173	)			(161	)
Loss before income taxes			(926	)			(1,202	)
Income tax expense			—				—
Net loss		$	(926	)		$	(1,202	)
Net loss per share:
Basic and diluted		$	(0.13	)		$	(0.17	)
Shares used in calculation of net loss per share:
Basic and diluted			7,211				6,948

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250806598572/en/

Jennifer Rogerson

(808) 334-9455

investorrelations@cyanotech.com

Source: Cyanotech Corporation